Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.070
-0.250 (-10.78%)
At close: Nov 4, 2024, 4:00 PM
2.100
+0.030 (1.45%)
After-hours: Nov 4, 2024, 5:11 PM EST

Gain Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Revenue
-0.060.130.13--
Upgrade
Revenue Growth (YoY)
--58.40%-0.96%---
Upgrade
Cost of Revenue
11.4411.388.247.162.26-
Upgrade
Gross Profit
-11.44-11.32-8.11-7.03-2.26-
Upgrade
Selling, General & Admin
10.3210.939.686.841.250.56
Upgrade
Research & Development
0.11----1.59
Upgrade
Other Operating Expenses
---0.01-0.03-0.03-0.04
Upgrade
Operating Expenses
10.4210.939.686.811.222.1
Upgrade
Operating Income
-21.86-22.26-17.79-13.84-3.48-2.1
Upgrade
Interest Expense
------0.02
Upgrade
Interest & Investment Income
0.420.50.390.020-
Upgrade
Currency Exchange Gain (Loss)
-0.1-0.43-0.1-0.07-0.1-0.07
Upgrade
Pretax Income
-21.54-22.19-17.5-13.89-3.57-2.19
Upgrade
Income Tax Expense
0.060.080.0900.010.01
Upgrade
Net Income
-21.6-22.27-17.59-13.89-3.58-2.19
Upgrade
Net Income to Common
-21.6-22.27-17.59-13.89-3.58-2.19
Upgrade
Shares Outstanding (Basic)
1613121032
Upgrade
Shares Outstanding (Diluted)
1613121032
Upgrade
Shares Change (YoY)
35.04%9.49%16.90%279.11%19.17%-
Upgrade
EPS (Basic)
-1.33-1.71-1.48-1.37-1.33-0.97
Upgrade
EPS (Diluted)
-1.33-1.71-1.48-1.37-1.33-0.97
Upgrade
Free Cash Flow
-18.99-18.88-14.81-12.46-3.26-1.88
Upgrade
Free Cash Flow Per Share
-1.17-1.45-1.25-1.23-1.22-0.84
Upgrade
Operating Margin
--40336.86%-13410.18%-10332.05%--
Upgrade
Profit Margin
--40354.33%-13262.02%-10371.70%--
Upgrade
Free Cash Flow Margin
--34217.53%-11166.38%-9303.42%--
Upgrade
EBITDA
-21.82-22.22-17.76-13.82-3.47-2.1
Upgrade
D&A For EBITDA
0.040.040.030.020.010
Upgrade
EBIT
-21.86-22.26-17.79-13.84-3.48-2.1
Upgrade
Revenue as Reported
-0.060.140.160.030.04
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.